Navigation Links
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment
Date:9/18/2007

HONOLULU, Sept. 18 Breast cancer survivors who took a weekly dose of risedronate, sold as Actonel, lost significantly less bone than those who did not take the drug, according to a two-year study from the University of Pittsburgh School of Medicine presented this week at the 29th annual meeting of the American Society for Bone and Mineral Research. Scientific sessions continue through Wednesday at the Hawaii Convention Center.

Susan Greenspan, M.D., director of the Osteoporosis Prevention and Treatment Center and Bone Health program at the University of Pittsburgh Medical Center, and colleagues evaluated 87 women, mean age 50, enrolled in the Prevention of Osteoporosis in Postmenopausal Women with Breast Cancer Following Chemotherapy study. All participants in the randomized, double-blind trial received calcium and vitamin D supplements. However, half took 35 milligrams of risedronate once a week while others took a placebo.

Chemotherapy drugs and other medical treatments for breast cancer are known to induce menopause, which can kick-start bone loss, putting survivors at risk for osteoporotic fractures, said Dr. Greenspan, an internationally respected osteoporosis researcher and professor of medicine at Pitt. This study also looked at changes in spine and hip bone mineral density, as well as evidence of bone breakdown.

Ninety-seven percent of study participants had normal or low bone mass at enrollment. At baseline, many were taking tamoxifen, a breast cancer drug aimed at estrogen-sensitive tumors that also is sometimes used as a preventive therapy by women at high risk for breast cancer.

While tamoxifen can have a positive impact on bone in postmenopausal women, a small percentage of women were taking aromatase inhibitors (also used for prevention), which can have a negative effect on bone. During the second year of the study, about half the women began taking aromatase inhibitors and stopped taking tamoxifen.

After 24 months, women in the placebo group had significant bone loss in the spine and hip that we didnt see in women taking risedronate, noted Dr. Greenspan. In fact, women taking risedronate had a bone density much higher in the spine and hip than women in the placebo group. The researchers also observed that the greatest bone loss was found in women on aromatase inhibitors. Even so, risedronate continued to be successful in preventing bone loss.

We conclude that once weekly doses of risedronate improves bone density and prevents excess bone loss in breast cancer survivors, the researchers noted.


'/>"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Yale Cancer Center Answers: A New Weekly Radio Progam on WNPR
3. New treatment for Osteoporosis
4. Osteoporosis in men
5. Patients With Severe Hemophilia At Risk Of Developing Osteoporosis
6. Osteoporosis Drugs: right time to take-off
7. Fluoride Found Effective in Osteoporosis
8. Cement injections linked to osteoporosis
9. Cure for osteoporosis in prostate cancer patients
10. Mutation connected to Osteoporosis
11. Osteoporosis associated with Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that ... reduce the frequency and level of relapse. , At the 2016 ... Purpose,” will explore the critical tasks of the recovery phase and beyond including ...
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV ... the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream ... Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. ... , Chairman and CEO, will be presenting at Source Capital ... New York, NY at 2:15 p.m. ET on ... an Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... replay approximately one hour after the conclusion of the live ...
(Date:2/5/2016)... 5, 2016 --> ... states that the global active pharmaceuticals ingredients (APIs) market ... to reach US$185.9 bn by 2020. It is expected ... to 2020. The title of the report is "Active ... Geography, and by Therapeutic Area) - Global Industry Analysis, ...
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
Breaking Medicine Technology: